818 related articles for article (PubMed ID: 19016706)
21. Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo.
Arca E; Taştan HB; Erbil AH; Sezer E; Koç E; Kurumlu Z
J Dermatol; 2006 May; 33(5):338-43. PubMed ID: 16700666
[TBL] [Abstract][Full Text] [Related]
22. Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial.
Dell'Anna ML; Mastrofrancesco A; Sala R; Venturini M; Ottaviani M; Vidolin AP; Leone G; Calzavara PG; Westerhof W; Picardo M
Clin Exp Dermatol; 2007 Nov; 32(6):631-6. PubMed ID: 17953631
[TBL] [Abstract][Full Text] [Related]
23. Double-blind placebo-controlled study of autologous transplanted epidermal cell suspensions for repigmenting vitiligo.
van Geel N; Ongenae K; De Mil M; Haeghen YV; Vervaet C; Naeyaert JM
Arch Dermatol; 2004 Oct; 140(10):1203-8. PubMed ID: 15492182
[TBL] [Abstract][Full Text] [Related]
24. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs Narrowband-UV-B therapy.
Yones SS; Palmer RA; Garibaldinos TM; Hawk JL
Arch Dermatol; 2007 May; 143(5):578-84. PubMed ID: 17519217
[TBL] [Abstract][Full Text] [Related]
25. Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus.
Lubaki LJ; Ghanem G; Vereecken P; Fouty E; Benammar L; Vadoud-Seyedi J; Dell'Anna ML; Briganti S; Picardo M; Heenen M
Arch Dermatol Res; 2010 Mar; 302(2):131-7. PubMed ID: 19547993
[TBL] [Abstract][Full Text] [Related]
26. A double-blind, randomized trial of 0.05% betamethasone vs. topical catalase/dismutase superoxide in vitiligo.
Sanclemente G; Garcia JJ; Zuleta JJ; Diehl C; Correa C; Falabella R
J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1359-64. PubMed ID: 18624857
[TBL] [Abstract][Full Text] [Related]
27. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo.
Passeron T; Ostovari N; Zakaria W; Fontas E; Larrouy JC; Lacour JP; Ortonne JP
Arch Dermatol; 2004 Sep; 140(9):1065-9. PubMed ID: 15381545
[TBL] [Abstract][Full Text] [Related]
28. A randomized placebo-controlled double-blind study of levamisole in the treatment of limited and slowly spreading vitiligo.
Agarwal S; Ramam M; Sharma VK; Khandpur S; Pal H; Pandey RM
Br J Dermatol; 2005 Jul; 153(1):163-6. PubMed ID: 16029343
[TBL] [Abstract][Full Text] [Related]
29. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting.
van de Kerkhof PC; van der Valk PG; Swinkels OQ; Kucharekova M; de Rie MA; de Vries HJ; Damstra R; Oranje AP; de Waard-van der Spek FB; van Neer P; Lijnen RL; Kunkeler AC; van Hees C; Haertlein NG; Hol CW
Br J Dermatol; 2006 Oct; 155(4):800-7. PubMed ID: 16965431
[TBL] [Abstract][Full Text] [Related]
30. Monochromatic excimer light 308 nm in monotherapy and combined with topical khellin 4% in the treatment of vitiligo: a controlled study.
Saraceno R; Nisticò SP; Capriotti E; Chimenti S
Dermatol Ther; 2009; 22(4):391-4. PubMed ID: 19580584
[TBL] [Abstract][Full Text] [Related]
31. Long-term safety and efficacy of high-concentration (20 microg/g) tacalcitol ointment in psoriasis vulgaris.
Miyachi Y; Ohkawara A; Ohkido M; Harada S; Tamaki K; Nakagawa H; Hori Y; Nishiyama S
Eur J Dermatol; 2002; 12(5):463-8. PubMed ID: 12370136
[TBL] [Abstract][Full Text] [Related]
32. A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0·1% vs. clobetasol propionate 0·05% in childhood vitiligo.
Ho N; Pope E; Weinstein M; Greenberg S; Webster C; Krafchik BR
Br J Dermatol; 2011 Sep; 165(3):626-32. PubMed ID: 21457214
[TBL] [Abstract][Full Text] [Related]
33. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo.
Lepe V; Moncada B; Castanedo-Cazares JP; Torres-Alvarez MB; Ortiz CA; Torres-Rubalcava AB
Arch Dermatol; 2003 May; 139(5):581-5. PubMed ID: 12756094
[TBL] [Abstract][Full Text] [Related]
34. Vitiligo treatment with monochromatic excimer light and tacrolimus: results of an open randomized controlled study.
Nisticò S; Chiricozzi A; Saraceno R; Schipani C; Chimenti S
Photomed Laser Surg; 2012 Jan; 30(1):26-30. PubMed ID: 22054204
[TBL] [Abstract][Full Text] [Related]
35. Tacalcitol: a useful adjunct to narrow-band ultraviolet-B phototherapy in vitiligo.
Sahu P; Jain VK; Aggarwal K; Kaur S; Dayal S
Photodermatol Photoimmunol Photomed; 2016 Sep; 32(5-6):262-268. PubMed ID: 27552149
[TBL] [Abstract][Full Text] [Related]
36. Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study.
Middelkamp-Hup MA; Bos JD; Rius-Diaz F; Gonzalez S; Westerhof W
J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):942-50. PubMed ID: 17659004
[TBL] [Abstract][Full Text] [Related]
37. Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients.
Fai D; Cassano N; Vena GA
J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):916-20. PubMed ID: 17659000
[TBL] [Abstract][Full Text] [Related]
38. Combination of 308-nm excimer laser with topical pimecrolimus for the treatment of childhood vitiligo.
Hui-Lan Y; Xiao-Yan H; Jian-Yong F; Zong-Rong L
Pediatr Dermatol; 2009; 26(3):354-6. PubMed ID: 19706108
[TBL] [Abstract][Full Text] [Related]
39. Effect of a preceding laser dermabrasion on the outcome of combined therapy with narrowband ultraviolet B and potent topical steroids for treating nonsegmental vitiligo in resistant localizations.
Bayoumi W; Fontas E; Sillard L; Le Duff F; Ortonne JP; Bahadoran P; Lacour JP; Passeron T
Br J Dermatol; 2012 Jan; 166(1):208-11. PubMed ID: 21824124
[TBL] [Abstract][Full Text] [Related]
40. Freckling promoted by topical tacalcitol in a Japanese boy with left eyelid vitiligo.
Oiso N; Kawada A
Pediatr Dermatol; 2012; 29(5):671-2. PubMed ID: 22011021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
